Click here to read the Cover Story, "Specialists weigh strengths, limitations of AMD and DME strategies currently at hand."
The clinical trials have purposefully strict inclusion and exclusion criteria to control the variables that might affect the outcomes of an intervention.
However, the real-world target patient population to whom the study results might be applied could be significantly more complex and heterogenous. Patients with concomitant geographic atrophy (GA) and neovascular age-related macular degeneration with active exudation are a prime example of this.
In the pivotal GA studies,